Discovery

Columbia-led trial reports 64% response rate in small Phase II for four-drug CXCR4 regimen

A quadruplet regimen combining the CXCR4 antagonist motixafortide (APHEXDA) with the anti-PD-1 antibody cemiplimab and standard chemotherapy produced a 64%...

Columbia-led trial reports 64% response rate in small Phase II for four-drug CXCR4 regimen

A four-drug regimen combining the CXCR4 antagonist motixafortide (APHEXDA) with cemiplimab and chemotherapy produced responses in seven of 11 treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to Phase II pilot data published August 21 in Nature Communications. The study pairs the early clinical signal with single-cell evidence that CXCR4 blockade may help reshape the immune-resistant PDAC tumor microenvironment.

The study enrolled 11 treatment-naïve patients with metastatic PDAC and treated them with the four-agent combination — referred to as MCGN — comprising motixafortide, cemiplimab, gemcitabine, and nab-paclitaxel. Corresponding authors Kenneth P. Olive, Benjamin Izar, and Gulam A. Manji led the work through Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center, with collaborators at Brown University's Legorreta Cancer Center, Memorial Sloan Kettering Cancer Center, the Huntsman Cancer Institute at the University of Utah, the University of North Carolina, and the Case Comprehensive Cancer Center.

Clinical findings

In the 11-patient pilot cohort, the regimen produced an objective response rate (ORR) of 64%, a confirmed partial response rate of 55%, and a disease control rate (DCR) of 91%, according to the paper. Four of the 11 patients remained progression-free after more than one year. Median progression-free survival and overall survival figures from the pilot phase have been reported at scientific meetings, though these are from a small, single-arm cohort without a contemporaneous comparator.

Motixafortide is FDA-approved under the brand name APHEXDA — in combination with filgrastim — for hematopoietic stem cell mobilization in multiple myeloma, marketed by BioLineRx. In the metastatic PDAC context it remains investigational.

Mechanism and single-cell correlatives

Cancer-associated fibroblasts in the PDAC tumor microenvironment (TME) secrete CXCL12, which signals through CXCR4 on immune cells to physically exclude cytotoxic T cells from the tumor — a principal reason checkpoint inhibitors have failed in this disease. Motixafortide blocks CXCR4, with the goal of disrupting this exclusion barrier and permitting T-cell infiltration that cemiplimab can then sustain.

Single-nucleus RNA sequencing (snRNA-seq) of serial biopsies in responding patients revealed decreased tumor heterogeneity and reduced epithelial-to-mesenchymal transition states compared with resistant patients. Responders showed enrichment of CXCL12-expressing cancer-associated fibroblasts, the paper reported, consistent with the proposed mechanism and potentially identifying a TME-based biomarker of response.

The AllSci BriefSystematic R&D and deal news. Daily.

Competitive context

Two prior attempts to combine CXCR4 blockade with checkpoint inhibition in PDAC produced limited clinical benefit. The MORPHEUS-PDAC trial of motixafortide plus the anti-PD-L1 antibody atezolizumab in pretreated patients showed insufficient efficacy across all atezolizumab combinations, according to results published in The Oncologist in April 2026. A Phase II study at Johns Hopkins (NCT04177810) pairing plerixafor, a different CXCR4 antagonist, with cemiplimab confirmed T-cell recruitment but identified immunosuppressive macrophage infiltration as a co-resistance mechanism, according to results published in OncoImmunology in 2025. The addition of gemcitabine and nab-paclitaxel in the current regimen addresses the hypothesis that chemotherapy-mediated cytotoxic activity and potential immunogenic priming are necessary to overcome residual resistance.

An earlier proof-of-concept for the CXCR4-plus-checkpoint-plus-chemotherapy approach came from the COMBAT/KEYNOTE-202 trial (NCT02826486), sponsored by Israel-based BioLineRx (Nasdaq: BLRX), which used motixafortide with pembrolizumab and a nanoliposomal irinotecan plus 5-FU/leucovorin backbone in previously treated patients. BioLineRx also provides motixafortide as drug supply for the current Columbia-sponsored trial; Regeneron provides cemiplimab.

Development status

Based on the pilot results, the trial (NCT04543071) has been amended to a randomized, multicenter Phase II expansion comparing MCGN against gemcitabine and nab-paclitaxel alone in treatment-naïve patients. BioLineRx has described this as the first large, multicenter, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line chemotherapy in metastatic PDAC. A prespecified interim/futility analysis was anticipated to read out in 2026, according to BioLineRx's 2025 annual financial results published in March 2026.

The study is limited by the small pilot cohort size, the absence of a randomized comparator in the reported data, and the single-institution design of the pilot phase.


Spot something wrong? Report an issue with this article